technetium-tc-99m-depreotide and Meningioma

For more than a decade, In-111 octreotide has been known to accumulate in meningiomas as a result of the expression of subtype 2 somatostatin receptors. Improved imaging characteristics can be expected with the recently developed radiotracer Tc-99m depreotide, which also binds to subtype 2 somatostatin receptors.. The authors examined a patient with intraorbital and extracranial recurrent meningioma using SPECT with Tc-99m depreotide and In-111 octreotide. The tumor-to-background ratios in the lesions were compared and the findings were correlated with histopathologic findings.. Although the tumor-to-background ratios were higher for the In-111-labeled tracer in the largest tumor lesion (5.7 versus 3.3), SPECT with the Tc-99m-labeled compound showed a proved second site of recurrence as a result of the better resolution that can be achieved with that isotope. CONCLUSIONS SPECT: with Tc-99m depreotide appears to be clinically useful for detecting recurrent meningiomas with higher resolution and may outperform In-111 octreotide imaging in patients with meningiomas.

Topics: Eye Neoplasms; Female; Humans; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Recurrence, Local; Octreotide; Organotechnetium Compounds; Radionuclide Imaging; Radiopharmaceuticals; Somatostatin